JP7692918B6 - 抗ｌａｇ３モノクローナル抗体、その製造方法および使用 - Google Patents

抗ｌａｇ３モノクローナル抗体、その製造方法および使用

Info

Publication number
JP7692918B6
JP7692918B6 JP2022544146A JP2022544146A JP7692918B6 JP 7692918 B6 JP7692918 B6 JP 7692918B6 JP 2022544146 A JP2022544146 A JP 2022544146A JP 2022544146 A JP2022544146 A JP 2022544146A JP 7692918 B6 JP7692918 B6 JP 7692918B6
Authority
JP
Japan
Prior art keywords
lag3
seq
monoclonal antibody
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022544146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510982A5 (cg-RX-API-DMAC10.html
JP7692918B2 (ja
JP2023510982A (ja
Inventor
戈 宋
輝 肖
虹霖 何
旭 許
偉東 姜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Henlius Biopharmaceutical Co Ltd
Shanghai Henlius Biotech Inc
Original Assignee
Shanghai Henlius Biopharmaceutical Co Ltd
Shanghai Henlius Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Henlius Biopharmaceutical Co Ltd, Shanghai Henlius Biotech Inc filed Critical Shanghai Henlius Biopharmaceutical Co Ltd
Publication of JP2023510982A publication Critical patent/JP2023510982A/ja
Publication of JP2023510982A5 publication Critical patent/JP2023510982A5/ja
Publication of JP7692918B2 publication Critical patent/JP7692918B2/ja
Application granted granted Critical
Publication of JP7692918B6 publication Critical patent/JP7692918B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022544146A 2020-01-21 2021-01-19 抗ｌａｇ３モノクローナル抗体、その製造方法および使用 Active JP7692918B6 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010069008 2020-01-21
CN202010069008.9 2020-01-21
PCT/CN2021/072610 WO2021147837A1 (zh) 2020-01-21 2021-01-19 抗lag3单克隆抗体及其制备方法和应用

Publications (4)

Publication Number Publication Date
JP2023510982A JP2023510982A (ja) 2023-03-15
JP2023510982A5 JP2023510982A5 (cg-RX-API-DMAC10.html) 2024-01-26
JP7692918B2 JP7692918B2 (ja) 2025-06-16
JP7692918B6 true JP7692918B6 (ja) 2025-07-17

Family

ID=76993109

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022544146A Active JP7692918B6 (ja) 2020-01-21 2021-01-19 抗ｌａｇ３モノクローナル抗体、その製造方法および使用

Country Status (10)

Country Link
US (1) US20230074657A1 (cg-RX-API-DMAC10.html)
EP (1) EP4095159A4 (cg-RX-API-DMAC10.html)
JP (1) JP7692918B6 (cg-RX-API-DMAC10.html)
KR (1) KR20220131279A (cg-RX-API-DMAC10.html)
CN (1) CN114945595A (cg-RX-API-DMAC10.html)
AU (1) AU2021210029A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022013544A2 (cg-RX-API-DMAC10.html)
CA (1) CA3165211A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021147837A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202208339B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
EP4410835A4 (en) * 2021-09-29 2025-09-24 Akeso Biopharma Inc ANTI-LAG3 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE
WO2023138677A1 (en) * 2022-01-24 2023-07-27 Crown Bioscience Inc. (Taicang) Novel anti-lag3 antibodies and derivative products
CN119950708B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的药物制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110172099A (zh) 2018-08-16 2019-08-27 上海健信生物医药科技有限公司 抗lag-3人源化单克隆抗体分子，抗原结合片段及其医药用途
CN110204614A (zh) 2018-02-28 2019-09-06 广州誉衡生物科技有限公司 抗人lag-3单克隆抗体及其制备方法和用途
CN110305215A (zh) 2018-03-20 2019-10-08 基石药业 新型抗lag-3抗体多肽
CN110343179A (zh) 2018-04-02 2019-10-18 上海博威生物医药有限公司 结合淋巴细胞活化基因-3(lag-3)的抗体及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
RS64268B1 (sr) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CN114853891A (zh) * 2015-07-22 2022-08-05 索伦托药业有限公司 与lag3结合的抗体治疗剂
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
US20190330336A1 (en) * 2015-11-19 2019-10-31 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
SI4339615T1 (sl) 2016-09-16 2026-01-30 Shanghai Henlius Biotech, Inc. Protitelesa anti-pd-1 za uporabo pri zdravljenju raka
UA128387C2 (uk) * 2017-04-05 2024-07-03 Ф. Хоффманн-Ля Рош Аг Антитіло до lag3
US11339218B2 (en) * 2017-05-10 2022-05-24 Zhejiang Shimai Pharmaceutical Co., Ltd. Human monoclonal antibodies against LAG3 and uses thereof
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110204614A (zh) 2018-02-28 2019-09-06 广州誉衡生物科技有限公司 抗人lag-3单克隆抗体及其制备方法和用途
CN110305215A (zh) 2018-03-20 2019-10-08 基石药业 新型抗lag-3抗体多肽
CN110343179A (zh) 2018-04-02 2019-10-18 上海博威生物医药有限公司 结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
CN110172099A (zh) 2018-08-16 2019-08-27 上海健信生物医药科技有限公司 抗lag-3人源化单克隆抗体分子，抗原结合片段及其医药用途

Also Published As

Publication number Publication date
EP4095159A1 (en) 2022-11-30
EP4095159A4 (en) 2024-03-20
CA3165211A1 (en) 2021-07-29
US20230074657A1 (en) 2023-03-09
AU2021210029A1 (en) 2022-09-01
JP7692918B2 (ja) 2025-06-16
ZA202208339B (en) 2023-11-29
KR20220131279A (ko) 2022-09-27
JP2023510982A (ja) 2023-03-15
BR112022013544A2 (pt) 2022-09-06
WO2021147837A1 (zh) 2021-07-29
CN114945595A (zh) 2022-08-26

Similar Documents

Publication Publication Date Title
US12258411B2 (en) Anti-CCR8 antibodies and uses thereof
JP7692918B2 (ja) 抗ｌａｇ３モノクローナル抗体、その製造方法および使用
EP3575322B1 (en) Anti-pd-1 monoclonal antibody, and preparation method therefor and application thereof
JP6908722B2 (ja) 抗ｐｄ−１抗体及びその使用
CA2698382C (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
JP7727086B2 (ja) 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体及び応用
US12428482B2 (en) Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
CA2971491C (en) HUMAN ENDOTHELIN RECEPTOR BINDING ANTIBODIES AND THEIR USE
HK1247214B (zh) 一种pdl-1抗体、其药物组合物及其用途
CA3087105A1 (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
JP2020521504A (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
KR20220042258A (ko) 항 tigit 항체 및 그의 응용
AU2016319433A1 (en) Anti-EphA4 antibody
WO2022040345A1 (en) Anti-par-2 antibodies and methods of use thereof
JP2026016483A (ja) 抗ヒトｔｌｒ７抗体
IL298287A (en) Binding molecules for the treatment of cancer
KR20220035155A (ko) ETA 항체 및 TGF-β TRAP의 융합 단백질 및 이의 약제학적 조성물 및 응용
EP3981787A1 (en) Anti-connective tissue growth factor antibody and application thereof
JP7090557B2 (ja) Ｅｔａｒ抗体、ならびにその医薬組成物および使用
JP2025503202A (ja) 抗インターロイキン－１１抗体及びその使用
CN114075283A (zh) 结合人cd38的抗体、其制备方法和用途
JP7510209B2 (ja) ヘルパーＴ細胞ＴＧＦ－βシグナルを特異的に中和する二重特異性抗体、その薬物組成物およびその使用
HK40079690A (en) Anti-lag3 monoclonal antibody, and preparation method therefor and use thereof
TW202035457A (zh) 靶向cd137的抗體及其使用方法
TW202304982A (zh) 一種能與人內皮素受體特異性結合的抗體及其在糖尿病腎病及慢性腎病治療中的應用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240118

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250121

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250417

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250604

R150 Certificate of patent or registration of utility model

Ref document number: 7692918

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150